# LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

> **NCT06978088** · PHASE2 · RECRUITING · sponsor: **Zulfa Omer** · enrollment: 34 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma
- CLL/SLL
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** LP-168
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06978088
- **Lead sponsor:** Zulfa Omer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2029-06-01
- **Final completion:** 2034-06-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978088, "LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06978088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*